Presenters
Associate Professor in the School of Clinical Medicine
Prof. Nqoba Tsabedze
Course details
Cardiovascular death remains the leading cause of morbidity and mortality in patients living with T2D. SGLT2 inhibitors and GLP-1 RAs have data on the improvement outcomes in patients living with T2D and CV disease.
Estimated time to completion: 27 mins & 35 secs.
PC-ZA-101720